FDA Grants Breakthrough Device Designation to Onc.AI's AI-Powered Cancer Prognosis Tool
核心洞察
Onc.AI (搜索)'s Serial CT Response Score (搜索) (CTRS) AI model receives FDA Breakthrough Device Designation for its innovative approach to predicting mortality risk in metastatic non-small cell lung cancer (搜索) patients.
The AI model demonstrates superior performance compared to traditional RECIST 1.1 (搜索) criteria in predicting overall survival for patients receiving immunotherapy (搜索), as shown in a multi-institutional study.
The technology shows promise in transforming both clinical cancer care and oncology drug development through automated prognostic insights from routine CT scans.
Onc.AI (搜索), a digital health company specializing in AI-driven oncology solutions, has achieved a significant milestone with the FDA's Breakthrough Device Designation for its Serial CT Response Score (搜索) (CTRS) AI model. This innovative tool employs deep learning technology to analyze CT scans and categorize metastatic non-small cell lung cancer (搜索) patients into high- or low-mortality risk groups.
Clinical Validation and Performance
Recent findings presented at the Society for Immunotherapy of Cancer (搜索) (SITC) have demonstrated the model's enhanced capability in predicting overall survival for immunotherapy (搜索) patients. The multi-institutional study revealed that Serial CTRS outperforms conventional imaging assessment tools, offering more precise insights for personalized cancer care.
"We are honored to be awarded Breakthrough Device Designation for our Serial CTRS AI model," said Akshay Nanduri, CEO of Onc.AI (搜索). "Onc.AI aims to equip oncologists with vital, automated prognostic insights using routinely collected diagnostic imaging scans and ultimately improve treatment strategy and provide risk stratification throughout a cancer patient's journey."
Impact on Drug Development
The Serial CTRS technology extends beyond clinical applications, showing potential to revolutionize oncology drug development. The model has demonstrated superior performance compared to the standard RECIST 1.1 (搜索) criteria in predicting overall survival, positioning it as a valuable tool for clinical trial design and development decisions.
Dr. Dwight Owen, Associate Professor of Medicine and Head of Thoracic Oncology at The James Cancer Center (搜索) at OSU, expressed enthusiasm about the technology: "Having been involved in product definition and evaluating results throughout the evolution of this product, I look forward to seeing this breakthrough technology enter the clinic and impact early phase trials and clinical development."
Industry Collaboration and Support
The development of Serial CTRS has been strengthened through strategic partnerships, including collaboration with Flatiron Health (搜索). Jacqueline Law, VP of Corporate Strategy at Flatiron Health, noted: "As longstanding partners of Onc.AI (搜索), we are thrilled to see the application of Flatiron's high-quality, curated real-world data in the development and validation of regulatory-grade AI models for clinical use."
Onc.AI (搜索)'s innovative platform is supported by prominent institutional investors and the National Cancer Institute SBIR program, reflecting the broader healthcare industry's confidence in AI-driven solutions for oncology management.